Cornerstone Capital Inc. lifted its stake in Gilead Sciences (NASDAQ:GILD) by 22.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 62,966 shares of the biopharmaceutical company’s stock after acquiring an additional 11,730 shares during the period. Cornerstone Capital Inc.’s holdings in Gilead Sciences were worth $4,511,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Capital International Investors grew its stake in Gilead Sciences by 86.6% during the 3rd quarter. Capital International Investors now owns 11,217,015 shares of the biopharmaceutical company’s stock worth $908,803,000 after buying an additional 5,205,983 shares during the last quarter. Sanders Capital LLC grew its stake in Gilead Sciences by 102.9% during the 4th quarter. Sanders Capital LLC now owns 9,910,493 shares of the biopharmaceutical company’s stock worth $757,119,000 after buying an additional 5,026,015 shares during the last quarter. Skandinaviska Enskilda Banken AB publ grew its stake in Gilead Sciences by 230.0% during the 3rd quarter. Skandinaviska Enskilda Banken AB publ now owns 4,927,585 shares of the biopharmaceutical company’s stock worth $399,233,000 after buying an additional 3,434,450 shares during the last quarter. CI Global Investments Inc. grew its stake in Gilead Sciences by 5,461.1% during the 4th quarter. CI Global Investments Inc. now owns 3,317,627 shares of the biopharmaceutical company’s stock worth $237,675,000 after buying an additional 3,257,969 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership grew its stake in Gilead Sciences by 12,545.5% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 3,070,327 shares of the biopharmaceutical company’s stock worth $219,958,000 after buying an additional 3,046,047 shares during the last quarter. 77.91% of the stock is owned by hedge funds and other institutional investors.
In other news, EVP Gregg H. Alton sold 30,000 shares of the company’s stock in a transaction dated Thursday, January 11th. The stock was sold at an average price of $79.00, for a total value of $2,370,000.00. Following the sale, the executive vice president now owns 57,114 shares in the company, valued at $4,512,006. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director John C. Martin sold 50,000 shares of the company’s stock in a transaction dated Monday, April 2nd. The stock was sold at an average price of $73.14, for a total value of $3,657,000.00. Following the completion of the sale, the director now owns 3,067,762 shares in the company, valued at approximately $224,376,112.68. The disclosure for this sale can be found here. Insiders sold 426,934 shares of company stock worth $33,847,101 in the last 90 days. Company insiders own 1.30% of the company’s stock.
Gilead Sciences stock opened at $73.41 on Friday. The company has a current ratio of 2.74, a quick ratio of 2.67 and a debt-to-equity ratio of 1.53. The stock has a market cap of $98,310.29, a price-to-earnings ratio of 8.58, a PEG ratio of -1.73 and a beta of 1.19. Gilead Sciences has a fifty-two week low of $63.76 and a fifty-two week high of $89.54.
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.67 by $0.11. Gilead Sciences had a return on equity of 50.29% and a net margin of 17.73%. The business had revenue of $5.95 billion for the quarter, compared to the consensus estimate of $5.71 billion. During the same quarter in the previous year, the business earned $2.70 EPS. The company’s quarterly revenue was down 18.7% compared to the same quarter last year. research analysts forecast that Gilead Sciences will post 6.21 earnings per share for the current year.
The business also recently announced a quarterly dividend, which was paid on Thursday, March 29th. Stockholders of record on Friday, March 16th were paid a $0.57 dividend. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.52. The ex-dividend date was Thursday, March 15th. This represents a $2.28 dividend on an annualized basis and a dividend yield of 3.11%. Gilead Sciences’s dividend payout ratio is presently 26.64%.
Several brokerages recently weighed in on GILD. Barclays restated an “overweight” rating and set a $95.00 target price (up from $90.00) on shares of Gilead Sciences in a research note on Tuesday, March 6th. BidaskClub downgraded Gilead Sciences from a “hold” rating to a “sell” rating in a research note on Saturday, March 3rd. TheStreet downgraded Gilead Sciences from a “b-” rating to a “c” rating in a research note on Tuesday, February 6th. Mizuho set a $95.00 target price on Gilead Sciences and gave the stock a “buy” rating in a research note on Monday, February 5th. Finally, Maxim Group set a $94.00 target price on Gilead Sciences and gave the stock a “buy” rating in a research note on Tuesday, February 6th. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating, seventeen have assigned a buy rating and two have issued a strong buy rating to the company. Gilead Sciences currently has a consensus rating of “Buy” and a consensus price target of $88.61.
TRADEMARK VIOLATION WARNING: “Cornerstone Capital Inc. Buys 11,730 Shares of Gilead Sciences (GILD)” was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The legal version of this news story can be accessed at https://www.dispatchtribunal.com/2018/04/07/cornerstone-capital-inc-buys-11730-shares-of-gilead-sciences-gild.html.
About Gilead Sciences
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.